Gabapentin for the Management of Hot Flashes in Prostate Cancer Survivors: A Longitudinal Continuation Study – NCCTG Trial N00CB

BACKGROUND: Hot flashes are a complication of androgen deprivation therapy given to men with prostate cancer. A previous clinical study indicated that use of low dose gabapentin (900mg/day) was well-tolerated and decreased hot flash frequency to a moderate degree for 4 weeks. The purpose of this cur...

Full description

Saved in:
Bibliographic Details
Main Authors: Moraska, Amanda R., Atherton, Pamela J., Szydlo, Daniel W., Barton, Debra L., Stella, Philip J., Rowland, Kendrith M., Schaefer, Paul L., Krook, James, Bearden, James D., Loprinzi, Charles L.
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3075822/
https://ncbi.nlm.nih.gov/pubmed/20552926
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items